Table 4.

Hazard Ratios Predicting Onset of Type 2 Diabetes by Treatment Group

Treatment Group	Predictor Variables	Model 1 Hazard Ratio (95% CI)	Model 2 Hazard Ratio (95% CI)
Placebo N=1036	ADM Intermittent Use vs. No ADM use	1.47 (0.94–2.31)	1.42 (0.90–2.24)
	ADM Continuous Use vs. No ADM use	2.52 (1.31–4.83)*	2.46 (1.28–4.71)*
	Natural Log CRP	-	1.16 (1.01–1.34)*
Metformin N=1049	ADM Intermittent Use vs. No ADM use	1.02 (0.61–1.71)	0.98 (0.58–1.63)
	ADM Continuous Use vs. No ADM use	0.74 (0.29–1.88)	0.71 (0.28–1.80)
	Natural Log CRP	-	1.22 (1.05–1.41)*
Lifestyle N=1052	ADM Intermittent Use vs. No ADM use	2.08 (1.18–3.65)*	2.11 (1.20–3.71)*
	ADM Continuous Use vs. No ADM use	3.26 (1.53–6.93)*	3.06 (1.43–6.57)*
	Natural Log CRP	-	1.11 (0.91–1.35)

ADM = Antidepressant medication use; CRP = C-reactive protein.

^*p<.05. Model 1 = ADM Use and covariates predicting incident T2DM without log-transformed time-dependent CRP. Model 2 = ADM Use, log-transformed time-dependent CRP and covariates predicting T2DM onset. Models are adjusted for age, sex, race/ethnicity, education, baseline weight, baseline glucose, change in weight, BDI score, anti-inflammatory medications, estrogen, and statins. Additional analysis showed that there was no significant interaction between treatment group and time-dependent log-transformed CRP with onset of diabetes.